Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metrics

Marc Hafner, Laura Heiser, Elizabeth H. Williams, Mario Niepel, Nicholas J. Wang, James Korkola, Joe Gray, Peter K. Sorger

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Traditional means for scoring the effects of anti-cancer drugs on the growth and survival of cell lines is based on relative cell number in drug-treated and control samples and is seriously confounded by unequal division rates arising from natural biological variation and differences in culture conditions. This problem can be overcome by computing drug sensitivity on a per-division basis. The normalized growth rate inhibition (GR) approach yields per-division metrics for drug potency (GR 50) and efficacy (GR max) that are analogous to the more familiar IC 50 and E max values. In this work, we report GR-based, proliferation-corrected, drug sensitivity metrics for ∼4,700 pairs of breast cancer cell lines and perturbagens. Such data are broadly useful in understanding the molecular basis of therapeutic response and resistance. Here, we use them to investigate the relationship between different measures of drug sensitivity and conclude that drug potency and efficacy exhibit high variation that is only weakly correlated. To facilitate further use of these data, computed GR curves and metrics can be browsed interactively at http://www.GRbrowser.org/.

Original languageEnglish (US)
Article number170166
JournalScientific data
Volume4
DOIs
StatePublished - Nov 7 2017

Fingerprint

Breast Cancer
quantification
Quantification
Cancer
Drugs
cancer
Cells
drug
Metric
Line
Cell
Division
Efficacy
Resistance
Cell line
Breast cancer
Proliferation
Unequal
Scoring
proliferation

ASJC Scopus subject areas

  • Statistics and Probability
  • Information Systems
  • Education
  • Computer Science Applications
  • Statistics, Probability and Uncertainty
  • Library and Information Sciences

Cite this

Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metrics. / Hafner, Marc; Heiser, Laura; Williams, Elizabeth H.; Niepel, Mario; Wang, Nicholas J.; Korkola, James; Gray, Joe; Sorger, Peter K.

In: Scientific data, Vol. 4, 170166, 07.11.2017.

Research output: Contribution to journalArticle

Hafner, Marc ; Heiser, Laura ; Williams, Elizabeth H. ; Niepel, Mario ; Wang, Nicholas J. ; Korkola, James ; Gray, Joe ; Sorger, Peter K. / Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metrics. In: Scientific data. 2017 ; Vol. 4.
@article{121028e5a8744636b49fef6e8efba6e4,
title = "Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metrics",
abstract = "Traditional means for scoring the effects of anti-cancer drugs on the growth and survival of cell lines is based on relative cell number in drug-treated and control samples and is seriously confounded by unequal division rates arising from natural biological variation and differences in culture conditions. This problem can be overcome by computing drug sensitivity on a per-division basis. The normalized growth rate inhibition (GR) approach yields per-division metrics for drug potency (GR 50) and efficacy (GR max) that are analogous to the more familiar IC 50 and E max values. In this work, we report GR-based, proliferation-corrected, drug sensitivity metrics for ∼4,700 pairs of breast cancer cell lines and perturbagens. Such data are broadly useful in understanding the molecular basis of therapeutic response and resistance. Here, we use them to investigate the relationship between different measures of drug sensitivity and conclude that drug potency and efficacy exhibit high variation that is only weakly correlated. To facilitate further use of these data, computed GR curves and metrics can be browsed interactively at http://www.GRbrowser.org/.",
author = "Marc Hafner and Laura Heiser and Williams, {Elizabeth H.} and Mario Niepel and Wang, {Nicholas J.} and James Korkola and Joe Gray and Sorger, {Peter K.}",
year = "2017",
month = "11",
day = "7",
doi = "10.1038/sdata.2017.166",
language = "English (US)",
volume = "4",
journal = "Scientific data",
issn = "2052-4463",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metrics

AU - Hafner, Marc

AU - Heiser, Laura

AU - Williams, Elizabeth H.

AU - Niepel, Mario

AU - Wang, Nicholas J.

AU - Korkola, James

AU - Gray, Joe

AU - Sorger, Peter K.

PY - 2017/11/7

Y1 - 2017/11/7

N2 - Traditional means for scoring the effects of anti-cancer drugs on the growth and survival of cell lines is based on relative cell number in drug-treated and control samples and is seriously confounded by unequal division rates arising from natural biological variation and differences in culture conditions. This problem can be overcome by computing drug sensitivity on a per-division basis. The normalized growth rate inhibition (GR) approach yields per-division metrics for drug potency (GR 50) and efficacy (GR max) that are analogous to the more familiar IC 50 and E max values. In this work, we report GR-based, proliferation-corrected, drug sensitivity metrics for ∼4,700 pairs of breast cancer cell lines and perturbagens. Such data are broadly useful in understanding the molecular basis of therapeutic response and resistance. Here, we use them to investigate the relationship between different measures of drug sensitivity and conclude that drug potency and efficacy exhibit high variation that is only weakly correlated. To facilitate further use of these data, computed GR curves and metrics can be browsed interactively at http://www.GRbrowser.org/.

AB - Traditional means for scoring the effects of anti-cancer drugs on the growth and survival of cell lines is based on relative cell number in drug-treated and control samples and is seriously confounded by unequal division rates arising from natural biological variation and differences in culture conditions. This problem can be overcome by computing drug sensitivity on a per-division basis. The normalized growth rate inhibition (GR) approach yields per-division metrics for drug potency (GR 50) and efficacy (GR max) that are analogous to the more familiar IC 50 and E max values. In this work, we report GR-based, proliferation-corrected, drug sensitivity metrics for ∼4,700 pairs of breast cancer cell lines and perturbagens. Such data are broadly useful in understanding the molecular basis of therapeutic response and resistance. Here, we use them to investigate the relationship between different measures of drug sensitivity and conclude that drug potency and efficacy exhibit high variation that is only weakly correlated. To facilitate further use of these data, computed GR curves and metrics can be browsed interactively at http://www.GRbrowser.org/.

UR - http://www.scopus.com/inward/record.url?scp=85033462936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033462936&partnerID=8YFLogxK

U2 - 10.1038/sdata.2017.166

DO - 10.1038/sdata.2017.166

M3 - Article

C2 - 29112189

AN - SCOPUS:85033462936

VL - 4

JO - Scientific data

JF - Scientific data

SN - 2052-4463

M1 - 170166

ER -